Analysts predict that Amgen Inc. (NASDAQ:AMGN) will announce $5.74 billion in sales for the current quarter, according to Zacks. Seven analysts have provided estimates for Amgen’s earnings. The lowest sales estimate is $5.64 billion and the highest is $5.85 billion. Amgen reported sales of $5.81 billion during the same quarter last year, which would suggest a negative year-over-year growth rate of 1.2%. The firm is scheduled to report its next quarterly earnings results on Thursday, October 26th.

According to Zacks, analysts expect that Amgen will report full year sales of $5.74 billion for the current year, with estimates ranging from $22.60 billion to $23.03 billion. For the next year, analysts forecast that the company will post sales of $23.11 billion per share, with estimates ranging from $22.69 billion to $24.35 billion. Zacks’ sales calculations are an average based on a survey of research analysts that follow Amgen.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the prior year, the company posted $2.84 EPS. The company’s quarterly revenue was up 2.1% on a year-over-year basis.

A number of equities research analysts have recently commented on the company. Mizuho set a $195.00 price objective on Amgen and gave the company a “buy” rating in a research report on Saturday, May 6th. UBS AG reaffirmed a “neutral” rating and issued a $174.00 price objective (down previously from $175.00) on shares of Amgen in a research report on Monday, May 22nd. BMO Capital Markets reaffirmed a “buy” rating and issued a $198.00 price objective (down previously from $200.00) on shares of Amgen in a research report on Monday, May 22nd. Morgan Stanley lifted their target price on Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, June 13th. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $203.00 target price (up previously from $189.00) on shares of Amgen in a report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $186.04.

Shares of Amgen (NASDAQ:AMGN) traded up 1.31% during trading on Tuesday, hitting $170.37. The stock had a trading volume of 580,051 shares. Amgen has a 12-month low of $133.64 and a 12-month high of $184.21. The company has a market cap of $124.31 billion, a PE ratio of 15.52 and a beta of 1.35. The stock’s 50 day moving average is $173.92 and its 200-day moving average is $168.25.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be given a $1.15 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.74%. Amgen’s dividend payout ratio (DPR) is 41.93%.

WARNING: “Analysts Expect Amgen Inc. (AMGN) Will Post Quarterly Sales of $5.74 Billion” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/22/analysts-expect-amgen-inc-amgn-will-post-quarterly-sales-of-5-74-billion.html.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the sale, the senior vice president now directly owns 24,214 shares in the company, valued at $3,738,641.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Cable Hill Partners LLC increased its stake in shares of Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock worth $161,000 after buying an additional 26 shares during the period. Douglass Winthrop Advisors LLC increased its stake in shares of Amgen by 3.7% in the first quarter. Douglass Winthrop Advisors LLC now owns 223,517 shares of the medical research company’s stock worth $36,672,000 after buying an additional 8,068 shares during the period. Forte Capital LLC ADV increased its stake in shares of Amgen by 8.1% in the first quarter. Forte Capital LLC ADV now owns 18,294 shares of the medical research company’s stock worth $3,002,000 after buying an additional 1,369 shares during the period. Sheets Smith Wealth Management increased its stake in shares of Amgen by 211.2% in the first quarter. Sheets Smith Wealth Management now owns 5,007 shares of the medical research company’s stock worth $821,000 after buying an additional 3,398 shares during the period. Finally, Gulf International Bank UK Ltd increased its stake in shares of Amgen by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 231,871 shares of the medical research company’s stock worth $38,043,000 after buying an additional 3,275 shares during the period. Institutional investors own 79.12% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Get a free copy of the Zacks research report on Amgen (AMGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.